Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/tumor-cell-resistance-to-death-receptor-induced-apoptosis-through-60nsFQgp9S
References (41)
-
C. Scaffidi, I. Schmitz, J. Zha, S. Korsmeyer, P. Krammer, M. Peter (1999)
Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells*The Journal of Biological Chemistry, 274
-
M. Wei, W. Zong, E. Cheng, T. Lindsten, V. Panoutsakopoulou, Andrea Ross, K. Roth, G. MacGregor, C. Thompson, S. Korsmeyer (2001)
Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 292
-
Robert Eskes, S. Desagher, B. Antonsson, J. Martinou (2000)
Bid Induces the Oligomerization and Insertion of Bax into the Outer Mitochondrial MembraneMolecular and Cellular Biology, 20
-
M. Muzio, A. Chinnaiyan, F. Kischkel, K. O’Rourke, A. Shevchenko, J. Ni, C. Scaffidi, J. Bretz, Mei Zhang, R. Gentz, M. Mann, P. Krammer, M. Peter, V. Dixit (1996)
FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling ComplexCell, 85
-
F. Kischkel, S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P. Krammer, M. Peter (1995)
Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor.The EMBO Journal, 14
-
M. Perucho (1996)
Cancer of the microsatellite mutator phenotype.Biological chemistry, 377 11
-
A. Chinnaiyan, Uttara Prasad, Sunita Shankar, D. Hamstra, Murthy Shanaiah, T. Chenevert, B. Ross, A. Rehemtulla (2000)
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy.Proceedings of the National Academy of Sciences of the United States of America, 97 4
-
Honglin Li, Hong Zhu, Chi-jie Xu, Junying Yuan (1998)
Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of ApoptosisCell, 94
-
I. Pollack, M. Erff, A. Ashkenazi (2001)
Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 5
-
M. Sprick, M. Weigand, M. Weigand, E. Rieser, C. Rauch, P. Juo, J. Blenis, P. Krammer, H. Walczak (2000)
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2.Immunity, 12 6
-
Y. Ionov, H. Yamamoto, S. Krajewski, John Reed, M. Perucho (2000)
Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution.Proceedings of the National Academy of Sciences of the United States of America, 97 20
-
J. Medema, J. Jong, T. Hall, C. Melief, R. Offringa (1999)
Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory ProteinThe Journal of Experimental Medicine, 190
-
Xu Luo, I. Budihardjo, Hua Zou, C. Slaughter, Xiaodong Wang (1998)
Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death ReceptorsCell, 94
-
Xiao-Ming Yin, Kun Wang, A. Gross, Yongge Zhao, S. Zinkel, B. Klocke, K. Roth, S. Korsmeyer (1999)
Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosisNature, 400
-
M. Djerbi, V. Screpanti, A. Catrina, B. Bogen, P. Biberfeld, A. Grandien (1999)
The Inhibitor of Death Receptor Signaling, Flice-Inhibitory Protein Defines a New Class of Tumor Progression FactorsThe Journal of Experimental Medicine, 190
-
R. Pitti, S. Marsters, D. Lawrence, M. Roy, F. Kischkel, P. Dowd, A. Huang, C. Donahue, S. Sherwood, Daryl Baldwin, P. Godowski, W. Wood, A. Gurney, K. Hillan, R. Cohen, A. Goddard, D. Botstein, A. Ashkenazi (1998)
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancerNature, 396
-
A. Ashkenazi, V. Dixit (1998)
Death receptors: signaling and modulation.Science, 281 5381
-
F. Kischkel, David Lawrence, A. Chuntharapai, P. Schow, K. Kim, A. Ashkenazi (2000)
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.Immunity, 12 6
-
Lin Zhang, Jian Yu, B. Park, K. Kinzler, B. Vogelstein (2000)
Role of BAX in the apoptotic response to anticancer agents.Science, 290 5493
-
A. Chuntharapai, Kelly Dodge, K. Grimmer, K. Schroeder, S. Marsters, H. Koeppen, A. Ashkenazi, K. Kim (2001)
Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4The Journal of Immunology, 166
-
J. Qin, Vijaya Chaturvedi, B. Bonish, B. Nickoloff (2001)
Avoiding premature apoptosis of normal epidermal cellsNature Medicine, 7
-
T. Lindsten, Andrea Ross, Ayala King, W. Zong, J. Rathmell, Helena Shiels, E. Ulrich, K. Waymire, Patryce Mahar, K. Frauwirth, Yifeng Chen, M. Wei, Vicki Eng, David Adelman, M. Simon, A. Ma, Jeffrey Golden, G. Evan, S. Korsmeyer, Grant MacGregor, Craig Thompson (2000)
The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues.Molecular cell, 6 6
-
A. Ashkenazi, V. Dixit (1999)
Apoptosis control by death and decoy receptors.Current opinion in cell biology, 11 2
-
H. Walczak, Robert Miller, K. Ariail, B. Gliniak, T. Griffith, M. Kubin, Wilson Chin, Jon Jones, A. Woodward, Tiep Le, Craig Smith, P. Smolak, R. Goodwin, C. Rauch, J. Schuh, D. Lynch (1999)
Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivoNature Medicine, 5
-
A. Gross, Xiao-Ming Yin, Kun Wang, M. Wei, J. Jockel, C. Milliman, H. Erdjument-Bromage, P. Tempst, S. Korsmeyer (1999)
Caspase Cleaved BID Targets Mitochondria and Is Required for Cytochrome c Release, while BCL-XL Prevents This Release but Not Tumor Necrosis Factor-R1/Fas Death*The Journal of Biological Chemistry, 274
-
I. Nicoletti, G. Migliorati, M. Pagliacci, F. Grignani, C. Riccardi (1991)
A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.Journal of immunological methods, 139 2
-
M. Wei, T. Lindsten, V. Mootha, S. Weiler, A. Gross, M. Ashiya, C. Thompson, S. Korsmeyer (2000)
tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c.Genes & development, 14 16
-
D. Green (2000)
Apoptotic Pathways Paper Wraps Stone Blunts ScissorsCell, 102
-
D. Lawrence, Z. Shahrokh, S. Marsters, Kirsten Achilles, Danny Shih, B. Mounho, K. Hillan, K. Totpal, L. Deforge, P. Schow, J. Hooley, S. Sherwood, R. Pai, Susan Leung, L. Khan, B. Gliniak, J. Bussiere, Craig Smith, S. Strom, S. Kelley, Judith Fox, Deborah Thomas, A. Ashkenazi (2001)
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versionsNature Medicine, 7
-
Sophie Roy, Donald Nicholson (2000)
Cross-talk in cell death signalingThe Journal of experimental medicine, 192 8
-
N. Rampino, H. Yamamoto, Y. Ionov, Y. Li, H. Sawai, John Reed, M. Perucho (1997)
Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator PhenotypeScience, 275
-
J. Bodmer, N. Holler, S. Reynard, P. Vinciguerra, P. Schneider, P. Juo, J. Blenis, J. Tschopp (2000)
TRAIL receptor-2 signals apoptosis through FADD and caspase-8Nature Cell Biology, 2
-
A. Chinnaiyan, K. O’Rourke, Brian Lane, V. Dixit (1997)
Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell DeathScience, 275
-
A. Ashkenazi, R. Pai, S. Fong, Susan Leung, David Lawrence, S. Marsters, Christine Blackie, Ling Chang, Amy McMurtrey, Andrea Hebert, L. Deforge, I. Koumenis, D. Lewis, Louise Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, R. Schwall (1999)
Safety and antitumor activity of recombinant soluble Apo2 ligand.The Journal of clinical investigation, 104 2
-
M. Boldin, T. Goncharov, Yury Goltseve, D. Wallach (1996)
Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor–Induced Cell DeathCell, 85
-
K. Ichikawa, Weimin Liu, Limin Zhao, Z. Wang, Di Liu, Toshiaki Ohtsuka, Huan-zhu Zhang, J. Mountz, W. Koopman, R. Kimberly, T. Zhou (2001)
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicityNature Medicine, 7
-
W. Roth, Stefan Isenmann, U. Naumann, S. Kügler, M. Bähr, J. Dichgans, A. Ashkenazi, M. Weller (1999)
Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.Biochemical and biophysical research communications, 265 2
-
G. Evan, T. Littlewood (1998)
A matter of life and cell death.Science, 281 5381
-
Gen Wu, T. Burns, E. McDonald, Wen Jiang, Ray Meng, I. Krantz, G. Kao, Dai-Di Gan, Junhao Zhou, R. Muschel, Stanley Hamilton, N. Spinner, S. Markowitz, Gary Wu, W. El-Deiry (1997)
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor geneNature Genetics, 17
-
D. Nicholson (2000)
From bench to clinic with apoptosis-based therapeutic agentsNature, 407
-
C. Lengauer, K. Kinzler, B. Vogelstein (1998)
Genetic instabilities in human cancersNature, 396
- Publisher
- Springer Journals
- Copyright
- Copyright © 2002 by Nature Publishing Group
- Subject
- Biomedicine; Biomedicine, general; Cancer Research; Metabolic Diseases; Infectious Diseases; Molecular Medicine; Neurosciences
- ISSN
- 1078-8956
- eISSN
- 1546-170X
- DOI
- 10.1038/nm0302-274
- Publisher site
- See Article on Publisher Site
Abstract
The importance of Bax for induction of tumor apoptosis through death receptors remains unclear. Here we show that Bax can be essential for death receptor–mediated apoptosis in cancer cells. Bax-deficient human colon carcinoma cells were resistant to death-receptor ligands, whereas Bax-expressing sister clones were sensitive. Bax was dispensable for apical death-receptor signaling events including caspase-8 activation, but crucial for mitochondrial changes and downstream caspase activation. Treatment of colon tumor cells deficient in DNA mismatch repair with the death-receptor ligand apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selected in vitro or in vivo for refractory subclones with Bax frameshift mutations including deletions at a novel site. Chemotherapeutic agents upregulated expression of the Apo2L/TRAIL receptor DR5 and the Bax homolog Bak in Bax −/− cells, and restored Apo2L/TRAIL sensitivity in vitro and in vivo. Thus, Bax mutation in mismatch repair–deficient tumors can cause resistance to death receptor–targeted therapy, but pre-exposure to chemotherapy rescues tumor sensitivity.
Journal
Nature Medicine – Springer Journals
Published: Mar 1, 2002